Brief: Ideaya Biosciences Completes Targeted Full Enrollment In Randomized Pivotal Phase 2/3 Trial (Optimum-02) Of Darovasertib In Combination With Crizotinib
11/12/2025 11:07
Dec 11 (Reuters) - IDEAYA Biosciences Inc IDYA.O: IDEAYA BIOSCIENCES COMPLETES TARGETED FULL ENROLLMENT IN RANDOMIZED PIVOTAL PHASE 2/3 TRIAL (OPTIMUM-02) OF DAROVASERTIB IN COMBINATION WITH CRIZOTINIB IN FIRST-LINE HLA*A2-NEGATIVE METASTATIC UVEAL MELANOMA IDEAYA BIOSCIENCES INC - TOPLINE DATA EXPECTED IN 1Q 2026 Source text: ID:nPn92sCpMa Further company coverage: IDYA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on IDEAYA Biosciences
See all newsBrief: Ideaya Biosciences And Servier Announce Data From Three Clinical Trials At Esmo 2026 Supporting The Potential Of Darovasertib To Become A Foundational New Therapy For Patients Across The Treatment Journey Of Uveal Melanoma
Brief: Ideaya Biosciences Announces The Promotion Of Dr. Michael White To President, Research And Development
Brief: Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Ideaya Biosciences Inc Reports Results For The Quarter Ended June 30: Earnings Summary
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj